Hiyasta Tablets (Tucidinostat) Launched in Japan for Relapsed or Refractory ATLL
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On October 20, 2021, Meiji Seika Pharma Co., Ltd. announced the launch of Hiyasta Tablets 100 mg (Tucidinostat) in Japan. This novel drug is indicated for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATLL).
Approval and Designation
Hiyasta was designated as an orphan drug by the Ministry of Health, Labour and Welfare (MHLW) in June 2021. The manufacturing and marketing authorization was obtained by Huya Japan, a subsidiary of the U.S.-based HUYABIO International, which developed the drug in collaboration with Meiji Seika Pharma.
Dosage and Administration
The recommended dosage for Hiyasta is 40 mg taken orally once daily, twice a week, with an interval of three or four days between doses. It should be administered after meals.
Clinical Significance
ATLL is an aggressive form of T-cell malignancy with limited treatment options, especially in the relapsed or refractory setting. Hiyasta, an HDAC inhibitor, offers a new oral treatment option that aims to improve clinical outcomes and maintain the quality of life for these patients.
Meiji Seika Pharma stated its commitment to ensuring the appropriate use of Hiyasta and providing essential medical information to healthcare professionals to support patients fighting this rare disease.
Source: Meiji Seika Pharma Press Release - Hiyasta Launch for ATLL
#Leukemia #Lymphoma #ATLL #Hiyasta #Tucidinostat #JapanMedicine #CancerTreatment #OrphanDrug
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1